Can Strength in Rental Business Drive INFU Stock Before Q3 Earnings?

InfuSystem (INFU) significantly exceeded Q2 2025 EPS estimates, reporting 12 cents against a 3-cent consensus, driven by higher treatment volumes in Patient Services' Oncology and Wound Care segments, and robust rental revenues in Device Solutions. For Q3 2025, analysts project $37.2 million in revenue (+5.3% YoY) and 8 cents EPS (flat YoY), with anticipated margin improvements from ERP upgrades and maturing rental contracts, though a strategic slowdown in Wound Care expansion and restructuring of biomedical services with GE Healthcare could introduce near-term fluctuations. Despite a Zacks Rank #3 and 0.00% Earnings ESP, INFU's shares have surged 75.2% over three months, outperforming the market, underpinned by long-term strategies including the Apollo Medical Supply acquisition and a shift towards asset-light, recurring revenue models, even as its 27.8x forward P/E trades at a premium to the industry average.

Analysis

InfuSystem (INFU) demonstrated strong operational performance in Q2 2025, reporting an EPS of 12 cents, significantly surpassing the Zacks Consensus Estimate of 3 cents, contributing to an average earnings surprise of 79.2% over the trailing four quarters. This outperformance was driven by higher treatment volumes and increased third-party payer collections in the Patient Services segment's Oncology and Wound Care businesses, alongside robust rental revenues from new customers in Device Solutions.

For Q3 2025, the Zacks Consensus Estimate projects revenues of $37.2 million, a 5.3% year-over-year improvement, with EPS expected to be flat at 8 cents. While ERP-related process upgrades are anticipated to improve margins, management's deliberate slowdown in Wound Care expansion for billing refinement and cost control, coupled with the restructuring of biomedical services with GE Healthcare, could introduce near-term margin variability.

Despite a Zacks Rank #3 and a 0.00% Earnings ESP, INFU's shares have surged 75.2% over the past three months, significantly outperforming the Medical - Products industry's 3.3% decline and the S&P 500's 9.7% growth. The company's forward 12-month P/E of 27.8x trades at a premium to the industry average of 20.1x, suggesting a higher valuation relative to expected sales growth, though it remains at a discount to some peers like Insulet (56.1x).

Long-term investment visibility is underpinned by strategic initiatives including the ERP implementation slated for early 2026, the May acquisition of Apollo Medical Supply to enhance wound care services, and an asset-light partnership with Smith & Nephew. These efforts aim to streamline operations, expand recurring revenue models, and drive sustainable returns with moderate capital expenditure.

Key Decisions for Investors

• Investors should closely monitor the upcoming Q3 earnings call for detailed insights into the impact of the Wound Care expansion slowdown and the GE Healthcare biomedical services restructuring on near-term margins and growth trajectory.
• Evaluate INFU's current valuation premium (27.8x forward P/E) against the potential for long-term margin expansion and recurring revenue growth driven by ERP implementation, the Apollo acquisition, and asset-light strategies.
• Consider the company's strong share price performance and outperformance against peers, while acknowledging the Zacks Rank #3 and 0.00% Earnings ESP, which suggests a lower probability of an earnings beat in the upcoming quarter.